Title 5, U.S.C., section 4314 (c) (4), which requires that members of performance review boards be appointed in a manner to ensure consistency, stability, and objectivity in performance appraisals and requires that notice of the appointment of an individual to serve as a member be published in the Federal Register.

The following persons will serve on the NIH Performance Review Board, which oversees the evaluation of performance appraisals of NIH Senior Executive Service (SES) members:

Alfred Johnson, Chair
Courtney Billet
Michael Gottesman
Kathleen Stephan
Darla Hayes
Michael Lauer
Lawrence Tabak

Dated: August 2, 2021.

Lawrence A. Tabak,
Principal Deputy Director, National Institutes of Health.

[FR Doc. 2021–17039 Filed 8–9–21; 8:45 am]
BILLING CODE 4140–01–P

---

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Multi-Domain Amphipathic Helical Peptide for Use as A Human Therapeutic in Patients With Atherosclerotic Cardiovascular Disease, Including Patients Undergoing Cardiovascular Surgery Who Are at risk of Acute Kidney Injury

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Heart, Lung, and Blood Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Phyxius Therapeutics, Inc., a start-up company incorporated as a C corporation under the laws of the state of Delaware, to practice the inventions covered by the patent estate listed in the SUPPLEMENTARY INFORMATION section of this notice. This is a first notice intended to apprise the public of a change in prospective licensee of the subject intellectual property rights in the stated field of use.

DATES: Only written comments and/or applications for a license which are received by the National Heart, Lung, and Blood Institute on or before August 25, 2021 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an exclusive patent license should be directed to: Michael Davis, J.D., Ph.D., Senior Technology Transfer Manager, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479, phone number 301–495–9032, or michael.davis4@nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

<table>
<thead>
<tr>
<th>NIH REF No.</th>
<th>Title</th>
<th>Patent Application No.</th>
<th>Filing Date</th>
<th>Issued Patent No.</th>
<th>Issue Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>E–114–2004–0–US–01.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>60/619,392</td>
<td>10/15/04</td>
<td>10/15/04</td>
<td></td>
</tr>
<tr>
<td>E–114–2004–0–PCT–02.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>PCT/US2005/</td>
<td>10/14/04</td>
<td>10/14/04</td>
<td></td>
</tr>
<tr>
<td>E–114–2004–0–AU–03.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>2005295640</td>
<td>10/14/04</td>
<td>2005295640</td>
<td>11/10/11</td>
</tr>
<tr>
<td>E–114–2004–0–CA–04.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>2584048</td>
<td>10/14/04</td>
<td>2584048</td>
<td>08/09/16</td>
</tr>
<tr>
<td>E–114–2004–0–EP–05.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>05815961.7</td>
<td>10/14/05</td>
<td>1812474</td>
<td>05/26/10</td>
</tr>
<tr>
<td>E–114–2004–0–JP–06.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>2007–536912</td>
<td>10/14/05</td>
<td>5,091,679</td>
<td>09/21/12</td>
</tr>
<tr>
<td>E–114–2004–0–US–08.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>12/497,443</td>
<td>07/02/09</td>
<td>8,071,746</td>
<td>12/06/11</td>
</tr>
<tr>
<td>E–114–2004–0–CH–11.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>05815961.7</td>
<td>10/14/05</td>
<td>1812474</td>
<td>05/26/10</td>
</tr>
<tr>
<td>E–114–2004–0–DE–12.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>05815961.7</td>
<td>10/14/05</td>
<td>1812474</td>
<td>05/26/10</td>
</tr>
<tr>
<td>E–114–2004–0–ES–13.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>05815961.7</td>
<td>10/14/05</td>
<td>1812474</td>
<td>05/26/10</td>
</tr>
<tr>
<td>E–114–2004–0–FR–14.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>05815961.7</td>
<td>10/14/05</td>
<td>1812474</td>
<td>05/26/10</td>
</tr>
<tr>
<td>E–114–2004–0–GB–15.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>05815961.7</td>
<td>10/14/05</td>
<td>1812474</td>
<td>05/26/10</td>
</tr>
<tr>
<td>E–114–2004–0–IT–16.</td>
<td>Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use.</td>
<td>05815961.7</td>
<td>10/14/05</td>
<td>1812474</td>
<td>05/26/10</td>
</tr>
</tbody>
</table>

All U.S. and foreign patents and applications claiming priority to any member of the above.

The patent rights in these inventions have been assigned or exclusively licensed to the Government of the United States of America.

The prospective exclusive license territory may be worldwide and in fields of use that may be limited to use as a human therapeutic in patients with atherosclerotic cardiovascular disease (ASCVD), including patients undergoing cardiovascular surgery who are at risk of acute kidney injury.

The patents listed above cover an invention directed to peptides or
peptide analogs with multiple amphipathic alpha helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. This invention is also directed to methods of identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells, and to methods of using multi-domain amphipathic alpha helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing. The prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice. The National Heart, Lung, and Blood Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Bruce D. Goldstein, Director, Office of Technology Transfer and Development, National Heart, Lung, and Blood Institute.

Please follow the instructions for submitting comments.

SUPPLEMENTARY INFORMATION: The Department of Homeland Security’s (DHS) Office of the Immigration Detention Ombudsman (OIDO) is an independent office tasked with resolving individual complaints from or about individuals in immigration detention regarding the potential violation of immigration detention standards or other potential misconduct. OIDO was established by Congress (Sec. 106 of the Consolidated Appropriations Act, 2020, Pub. L. 116–93). Its intake function is intended for use by individuals wishing to submit a complaint to OIDO. Information collected will provide the OIDO with details about the allegations the submitter seeks to have OIDO address.

The information collected on this form will allow OIDO to identify: (1) The individual submitting the complaint and their contact information; (2) the detained individual who is the subject of the complaint; (3) the government-owned or contracted facility where the individual is or was detained and for how long; and (4) relevant details about the complaint. All of this information will be used by OIDO to investigate, resolve, and if appropriate, provide redress.

The use of this form is the most efficient means for collecting and processing the required data. Initially, collection will be via a paper form, which may be obtained from OIDO staff conducting routine visits in detention facilities. The form will also be available for download from the OIDO website. The PDF form will be able to be completed online, printed out, and submitted to OIDO by email, mail, or fax, or handed to a staff member in a detention facility. After approval of the form described in this supporting statement, an electronic version will be developed so that submitters may complete and file via the OIDO website. The paper version will continue to be available; it will be noted on the form that using the paper method may result in processing delays for OIDO to complete data entry.

This information collection does not have an impact on small businesses or other small entities.

If this information is not collected, OIDO will not be able to accomplish its Congressional mandate to provide assistance to individuals who may be affected by misconduct, excessive force, or other violations of law or detention standards.


This information collection was constructed in compliance with regulations and authorities under the purview of the DHS Privacy Office, DHS OCIO, DHS Records Management, and OMB regulations regarding data collection, use, sharing, storage, information security, and retrieval of information.

There are no changes to the information being collected and there is no change to the estimated burden associated with this collection.

The Office of Management and Budget is particularly interested in comments which:

1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
2. Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to be collected; and
4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other